A&G Real Estate Partners Accepting Offers on 11 Medical Office Buildings in Northern New Jersey, Florida and New York

Investors can acquire individual or multiple assets or enter into a joint venture with the existing owner; offers must be submitted by October 18

A&G Real Estate Partners is now accepting offers on nine medical office properties in northern New Jersey and one each in Mount Kisco, New York, and Miramar, Florida.

Prospective buyers can purchase individual assets or acquire all 11 properties. Alternatively, the current owner—a medical doctor who built the portfolio over the last 10 years—would consider a joint venture.

All offers must be submitted by October 18.

“The owner has signed several new tenants recently and enjoys good working relationships with the rest,” noted A&G Co-President Emilio Amendola, who heads the New York-based firm’s real estate sales division.

“The portfolio, which has been historically under-managed because of cash-flow disruptions, is now primarily stabilized while still offering significant upside on several of the buildings,” Amendola said. “With reinvestment capital and professional approaches to leasing and management, buyers of any of these properties could achieve a healthy return on their investment.”

The New Jersey properties are in Oradell, Carlstadt, Hackensack, Jersey City, Glen Rock, Roseland and New Brunswick, along with two buildings in Fair Lawn.

The average building size, including assets in Mount Kisco, NY, and Miramar, FL. is about 27,000 square feet.

“Current tenants include labs, dental practices, business offices and regional surgery centers. New leases have just been signed that will increase revenue by more than $1 million,” Amendola said.

The 310,290-square-foot portfolio is 82 percent leased, with 12-month projected net operating income of approximately $5.5 million. Net Incomes on an individual property basis range from $150,000 to over $1,250,000 per year.

All 11 properties are in dense, well-populated markets with easy access to nearby hospitals and specialty clinics. For example, the 12,660-square-foot medical office building at 215 Easton Ave. in New Brunswick is across the street from Saint Peter’s University Hospital and serves as the cancer treatment center for this regional medical center.

The 72,715-square-foot medical office at 103-105 South Bedford Rd. in Mount Kisco is a quarter of a mile from Northwell Health’s Northern Westchester Hospital—a highly developed area with a high barrier to entry for new competitors.

To submit offers and for further information, visit https://www.agrep-sales.com/medicaloffice or contact Emilio Amendola, (631) 465-9507, emilio@agrep.com; Jamie Cote, (312) 203-6321, jcote@agrep.com; Katie Decoste, (773) 615-1292, kdecoste@agrep.com; or Christian Koulichkov, (617) 335-3940, ckoulichkov@agrep.com.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”